Skip to main content
Premium Trial:

Request an Annual Quote

Biosystemix to Analyze Data for S2K to Find Predictive Disease Markers

NEW YORK, June 21 (GenomeWeb News) - Biosystemix will develop computational models based on genomic and proteomic data for S2K, a Canadian consortium of researchers, the company said today.


Under the partnership, Biosystemix of Kingston, Canada, will use its data mining algorithms to discover predictive molecular markers and models from gene expression, proteomics, and cellular immune response data generated by S2K in the areas of HIV, HCV, rheumatoid arthritis, and transplant rejection.


Intellectual property resulting from the analyses will form the basis for commercial products such as diagnostic and prognostic markers, according to the company.


S2K's program, "Functional Genomics, Pharmacogenomics and Proteomics of the Immune Response in Health and Immune Related Disorders", is funded by Genome Canada and Genome Quebec.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more